Research Topics
| M S GordonSummaryAffiliation: University of Arizona Country: USA Publications
| Collaborators
|
Detail Information
Publications
Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancerM S Gordon
Indiana University School of Medicine, Indianapolis, IN, USA
J Clin Oncol 19:843-50. 2001..We investigated the safety and pharmacokinetics of a recombinant human monoclonal antibody to vascular endothelial growth factor (rhuMAb VEGF) in patients with cancer...- Managing patients treated with bevacizumab combination therapyMichael S Gordon
Arizona Cancer Center, Greater Phoenix Area, Scottsdale, Ariz 85258, USA
Oncology 69:25-33. 2005..The side-effect profile of bevacizumab makes it a suitable adjunct to standard chemotherapy in settings where efficacy has been demonstrated, and it is now approved for use in the USA, the European Union and other markets worldwide... - Novel antiangiogenic therapies for renal cell cancerMichael S Gordon
Arizona Cancer Center Greater Phoenix Area, University of Arizona College of Medicine, Scottsdale, Arizona 85258, USA
Clin Cancer Res 10:6377S-81S. 2004..Combinations of antiangiogenic agents either with other similarly acting drugs or as a component of a "cocktail" with other noncytotoxic therapies should be explored in this patient population... - Managing anemia in the cancer patient: old problems, future solutionsMichael S Gordon
Arizona Health Sciences Center, University of Arizona, Phoenix, Arizona 85012, USA
Oncologist 7:331-41. 2002.... 
Overexpression of tumor vascular endothelial growth factor A may portend an increased likelihood of progression in a phase II trial of bevacizumab and erlotinib in resistant ovarian cancerSetsuko K Chambers
Arizona Cancer Center, University of Arizona, Tucson, Arizona 85724 5024, USA
Clin Cancer Res 16:5320-8. 2010..This phase II trial evaluated bevacizumab plus erlotinib in platinum-resistant ovarian cancer; exploratory biomarker analyses, including that of tumor vascular endothelial growth factor A (VEGF-A), were also done...
A phase 2 clinical trial of nab-paclitaxel in previously treated and chemotherapy-naive patients with metastatic melanomaEvan M Hersh
Department of Medicine, Arizona Cancer Center, Tucson, AZ 85724, USA
Cancer 116:155-63. 2010..In the current study, the efficacy and safety of nab-paclitaxel were evaluated in previously treated and chemotherapy-naive patients with metastatic melanoma (MM)...- Renal cell carcinoma: rationale and development of therapeutic inhibitors of angiogenesisScot W Ebbinghaus
Division of Hematology Oncology, University of Arizona College of Medicine, Arizona Cancer Center, 1515 North Campbell Avenue, Tucson, AZ 85724 5024, USA
Hematol Oncol Clin North Am 18:1143-59, ix-x. 2004.... - A phase I study of weekly gemcitabine and docetaxel in patients with advanced cancer: a Hoosier Oncology Group StudyKristen N Ganjoo
Department of Medicine, Division of Hematology/Oncology, Indiana University and The Walther Cancer Institute, Indianapolis, USA
Oncology 62:299-304. 2002..The DLT was neutropenia. Disease stabilization suggests that this may be an active regimen in patients with metastatic pancreatic cancer... - Clinical activity of pertuzumab (rhuMAb 2C4), a HER dimerization inhibitor, in advanced ovarian cancer: potential predictive relationship with tumor HER2 activation statusMichael S Gordon
Arizona Cancer Center, Tuscon and Scottsdale, AZ, USA
J Clin Oncol 24:4324-32. 2006..CONCLUSION: Pertuzumab is well tolerated with a RR of 4.3% in heavily-pretreated OC patients. Further studies on pHER2 as a diagnostic are warranted... - A phase 1 trial of 2 dose schedules of ABT-510, an antiangiogenic, thrombospondin-1-mimetic peptide, in patients with advanced cancerMichael S Gordon
Premiere Oncology, Scottsdale, AZ, USA
Cancer 113:3420-9. 2008..The current study was designed to establish the safety of ABT-510 in the treatment of patients with advanced malignancies on a once-daily (QD) and twice-daily dosing schedule... - Safety, pharmacokinetics, and pharmacodynamics of AMG 102, a fully human hepatocyte growth factor-neutralizing monoclonal antibody, in a first-in-human study of patients with advanced solid tumorsMichael S Gordon
Premiere Oncology of Arizona, Scottsdale, Arizona 85258, USA
Clin Cancer Res 16:699-710. 2010..The aims were to assess the safety, pharmacokinetics, maximum tolerated dose, and antitumor activity of AMG 102, a fully human hepatocyte growth factor/scatter factor (HGF/SF)-neutralizing monoclonal antibody, in patients with solid tumors... - Phase II study of erlotinib in patients with locally advanced or metastatic papillary histology renal cell cancer: SWOG S0317Michael S Gordon
Premiere Oncology of Arizona, Scottsdale, AZ 85260, USA
J Clin Oncol 27:5788-93. 2009..In this trial, we evaluated the efficacy of erlotinib, an oral epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor in patients with advanced pRCC, a tumor type associated with wild-type von Hippel Lindau gene... - Tumor angiogenesis and novel antiangiogenic strategiesMichael S Gordon
Premiere Oncology of Arizona, Scottsdale, AZ 85258, USA
Int J Cancer 126:1777-87. 2010..quot;Published 2008 Wiley-Liss, Inc. This article is a US Government work, and, as such, is in the public domain in the United States of America.".. - Phase II trial of subcutaneous recombinant human interleukin 11 with subcutaneous recombinant human granulocyte-macrophage colony stimulating factor in patients with acute myeloid leukemia (AML) receiving high-dose cytarabine during induction: ECOG 3997Larry D Cripe
Indiana University Medical Center, Indianapolis, IN, United States
Leuk Res 30:823-7. 2006..I. 27-30 days) and 25 days (95% C.I. 24-29 days), respectively. The trial does not confirm the high CR rate observed in phase II trials, despite optimal supportive care... - Alpha-v integrins as therapeutic targets in oncologyJeffrey A Nemeth
Centocor, Inc, Radnor, Pennsylvania 19087, USA
Cancer Invest 25:632-46. 2007..This review focuses on the role of alpha(v) integrins in cancer progression, the current status of integrin-targeted agents in development, and strategies for the clinical development of anti-integrin therapies... - Inhibitors of growth factor receptors, signaling pathways and angiogenesis as therapeutic molecular agentsJocelyn Holash
Regeneron Pharmaceuticals, Tarrytown, NY, USA
Cancer Metastasis Rev 25:243-52. 2006 - Overview of anti-VEGF therapy and angiogenesis. Part 1: Angiogenesis inhibition in solid tumor malignanciesLee M Ellis
John Wayne Cancer Institute, Santa Monica, CA, USA
Clin Adv Hematol Oncol 4:suppl 1-10; quz 11-2. 2006..These other issues, including the biologic rationale for anti-VEGF therapy, as well as recent clinical trial data with anti-VEGF agents in colorectal, pancreatic, lung, kidney, and brease cancers, are discussed... - Use of epoetin in patients with cancer: evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of HematologyJ Douglas Rizzo
Medical College of Wisconsin, Milwaukee, WI 53226, USA
Blood 100:2303-20. 2002..Therefore, for anemic patients with hematologic malignancies it is recommended that physicians initiate conventional therapy and observe hematologic response before considering use of epoetin... - Phase I clinical study of pertuzumab, a novel HER dimerization inhibitor, in patients with advanced cancerDavid B Agus
Cedars Sinai Prostate Cancer Center and Medical Center, Los Angeles, CA 90048, USA
J Clin Oncol 23:2534-43. 2005..A clinical study was conducted to investigate safety and pharmacokinetics of pertuzumab and to perform a preliminary assessment of HER dimerization inhibition as a treatment strategy... - Combination of trastuzumab and tanespimycin (17-AAG, KOS-953) is safe and active in trastuzumab-refractory HER-2 overexpressing breast cancer: a phase I dose-escalation studyShanu Modi
Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
J Clin Oncol 25:5410-7. 2007..This phase I study examined whether a heat shock protein (Hsp) 90 inhibitor tanespimycin (17-AAG; KOS-953) could be administered safely in combination with trastuzumab at a dose that inhibits Hsp90 function in vivo in lymphocytes... - Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinomaDavid F McDermott
Department of Medicine, Division of Hematology Oncology, Beth Israel Deaconess Medical Center, 330 Brookline Ave, E KS 153, Boston, MA 02215, USA
J Clin Oncol 23:133-41. 2005..The Cytokine Working Group conducted a randomized phase III trial to determine the value of outpatient interleukin-2 (IL-2) and interferon alfa-2b (IFN) relative to high-dose (HD) IL-2 in patients with metastatic renal cell carcinoma... - The emerging role of darbepoetin alfa in the management of patients with cancerMichael S Gordon
J Support Oncol 2:2-3. 2004 - Innovations and challenges in renal cancer: consensus statement from the first international conferenceMichael B Atkins
Beth Israel Deaconess Medical Center, Boston, Massachusetts 02215, USA
Clin Cancer Res 10:6277S-81S. 2004 - Adjuvant high-dose bolus interleukin-2 for patients with high-risk renal cell carcinoma: a cytokine working group randomized trialJoseph I Clark
Cardinal Bernardin Cancer Center, Loyola University Medical Center, 2160 South First Avenue, Maywood, IL 60153, USA
J Clin Oncol 21:3133-40. 2003..This prospective, randomized, controlled phase III trial assessed high-dose bolus interleukin-2 (IL-2) postoperatively in patients with high-risk renal cell carcinoma (RCC)... - Use of epoetin in patients with cancer: evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of HematologyJ Douglas Rizzo
Medical College of Wisconsin, Milwaukee, WI, USA
J Clin Oncol 20:4083-107. 2002..Therefore, for anemic patients with hematologic malignancies, it is recommended that physicians initiate conventional therapy and observe hematologic response before considering use of epoetin... - Phase I trial of topotecan plus vinorelbine with/without filgrastim (G-CSF) in patients with refractory malignanciesNasser H Hanna
Department of Medicine, Indiana University, Indianapolis, Indiana, U.S.A
Am J Clin Oncol 25:337-9. 2002..Subsequent combinations of these drugs, if warranted, should focus on alternate doses, schedules, or routes of administration...